In addition to VISTA/PSGL-1 or VISTA/VSIG-3 interaction inhibitors, the literature has also described a small-molecule compound modulating VISTA in inflammatory contexts, which may be promising for the treatment of autoimmune diseases [286]. The gene discussed is VSIR; the disease is autoimmune disease.